Janus Henderson Group PLC Increases Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Janus Henderson Group PLC grew its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 848.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,700 shares of the biotechnology company's stock after purchasing an additional 21,201 shares during the quarter. Janus Henderson Group PLC's holdings in Repligen were worth $3,528,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Andra AP fonden acquired a new stake in Repligen in the 2nd quarter worth about $25,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 127 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the second quarter worth approximately $33,000. Finally, nVerses Capital LLC acquired a new position in Repligen in the 3rd quarter valued at $45,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

RGEN has been the topic of several recent research reports. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price target for the company. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $190.25.

Repligen Trading Up 0.5 %

Shares of NASDAQ RGEN traded up $0.74 during mid-day trading on Thursday, reaching $155.99. 495,600 shares of the company's stock were exchanged, compared to its average volume of 657,348. The company's 50-day moving average is $142.27 and its 200-day moving average is $141.78. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of -421.59, a PEG ratio of 4.48 and a beta of 0.96. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen's revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. Analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.